|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
*
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
WO2006021955A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Mor Research Applications Ltd. |
Use of bat monoclonal antibody for immunotherapy
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
EA021967B1
(ru)
*
|
2008-01-03 |
2015-10-30 |
Дзе Скриппс Рисерч Инститьют |
Доставка антител посредством модульного домена распознавания
|
|
PT2242773T
(pt)
*
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
NZ616382A
(en)
|
2009-04-20 |
2015-04-24 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17
|
|
PH12012501070A1
(en)
|
2009-12-08 |
2017-08-23 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
PT2542257T
(pt)
|
2010-03-01 |
2017-10-09 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
CA2800311A1
(en)
|
2010-05-11 |
2011-11-17 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
CN103534268B
(zh)
*
|
2010-10-20 |
2016-05-18 |
牛津生物疗法有限公司 |
抗体
|
|
DK2734205T3
(en)
|
2011-07-21 |
2018-06-14 |
Tolero Pharmaceuticals Inc |
Heterocyclic Protein Kinase Inhibitors
|
|
US8686119B2
(en)
|
2011-07-24 |
2014-04-01 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
US9610250B2
(en)
|
2012-04-12 |
2017-04-04 |
Yale University |
Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
|
|
JP6279466B2
(ja)
*
|
2012-04-27 |
2018-02-14 |
Ｊｃｒファーマ株式会社 |
新規な発現ベクター
|
|
JP2015520172A
(ja)
|
2012-05-31 |
2015-07-16 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｄｌｌ−４に結合する抗原結合蛋白質
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
EP2954327A1
(en)
|
2013-02-07 |
2015-12-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
|
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
KR20190126452A
(ko)
|
2013-11-01 |
2019-11-11 |
예일 유니버시티 |
면역요법용 모듈러 입자
|
|
US9580504B1
(en)
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
EP3092256B1
(en)
|
2014-01-10 |
2022-05-18 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
DK4001311T3
(da)
|
2014-07-09 |
2026-02-02 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
|
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
EP3191126B1
(en)
|
2014-09-13 |
2020-05-13 |
Novartis AG |
Combination therapies of alk inhibitors
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
JP6805142B2
(ja)
|
2014-11-21 |
2020-12-23 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ７３に対する抗体およびその使用
|
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
|
AR103268A1
(es)
|
2014-12-23 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra tigit
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
HUE045585T2
(hu)
|
2015-05-18 |
2020-01-28 |
Tolero Pharmaceuticals Inc |
Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
|
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
AU2016271111B2
(en)
|
2015-05-29 |
2022-04-28 |
Bristol-Myers Squibb Company |
Antibodies against OX40 and uses thereof
|
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
EP3313441B1
(en)
|
2015-06-24 |
2024-02-21 |
Janssen Biotech, Inc. |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
BR112018000366A2
(pt)
|
2015-08-07 |
2018-09-11 |
Pieris Pharmaceuticals Gmbh |
polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
|
|
JP6869987B2
(ja)
|
2015-09-01 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗ｐｄ−１抗体及びその使用方法
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
PE20181367A1
(es)
|
2015-09-30 |
2018-08-27 |
Janssen Biotech Inc |
Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN109071632B
(zh)
|
2016-02-05 |
2022-12-30 |
奥里尼斯生物科学私人有限公司 |
靶向性治疗剂及其用途
|
|
RU2018131123A
(ru)
|
2016-02-17 |
2020-03-17 |
Новартис Аг |
Антитела к tgf-бета2
|
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
|
WO2017155981A1
(en)
|
2016-03-07 |
2017-09-14 |
Massachusetts Institute Of Technology |
Protein-chaperoned t-cell vaccines
|
|
MA44483A
(fr)
|
2016-03-24 |
2019-01-30 |
Millennium Pharm Inc |
Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
BR112018071307A2
(pt)
|
2016-04-18 |
2019-02-26 |
Celldex Therapeutics, Inc. |
anticorpos agonistas que ligam cd40 humana e usos dos mesmos
|
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
US20190248893A1
(en)
|
2016-07-14 |
2019-08-15 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
CA3032826A1
(en)
|
2016-08-03 |
2018-02-08 |
Nextcure, Inc. |
Compositions and methods for modulating lair signal transduction
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
JP2019533645A
(ja)
|
2016-09-16 |
2019-11-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
|
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
KR102644544B1
(ko)
|
2016-09-21 |
2024-03-11 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
CN110114368B
(zh)
|
2016-10-24 |
2024-08-02 |
奥睿尼斯生物科学私人有限公司 |
靶向突变干扰素-γ及其用途
|
|
US11124577B2
(en)
|
2016-11-02 |
2021-09-21 |
Engmab Sàrl |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
IL307242B1
(en)
|
2016-12-07 |
2026-07-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
EP3576765B1
(en)
|
2017-02-06 |
2025-07-16 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
CN110290808B
(zh)
|
2017-02-10 |
2023-07-11 |
诺华股份有限公司 |
1-(4-氨基-5-溴-6-(1h-吡唑-1-基)嘧啶-2-基)-1h-吡唑-4-醇及其在治疗癌症中的用途
|
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc. |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ジスルフィド結合の還元を最小限にする抗体製造法
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
MX2019013132A
(es)
|
2017-05-25 |
2020-01-27 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas.
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
JP7301002B2
(ja)
|
2017-05-30 |
2023-06-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
|
|
US10933064B2
(en)
|
2017-05-31 |
2021-03-02 |
Novartis Ag |
Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
FI3641771T3
(fi)
|
2017-06-23 |
2026-08-11 |
Birdie Biopharmaceuticals Inc |
Farmaseuttisia koostumuksia
|
|
JP7012384B2
(ja)
|
2017-06-27 |
2022-02-14 |
ニューラクル サイエンス カンパニー リミテッド |
癌治療のための抗ｆａｍ１９ａ５抗体の用途
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
WO2019046856A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
|
|
JP7795860B2
(ja)
|
2017-09-07 |
2026-01-08 |
オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド |
プログラム細胞死タンパク質１に対する抗体
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
US11603410B2
(en)
|
2017-11-01 |
2023-03-14 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
US11324774B2
(en)
|
2018-01-05 |
2022-05-10 |
Augusta University Research Institute, Inc. |
Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
WO2019140150A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
AU2019210332A1
(en)
|
2018-01-22 |
2020-09-10 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
CN112566934B
(zh)
|
2018-01-23 |
2024-09-17 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
|
US12655186B2
(en)
|
2018-01-26 |
2026-06-16 |
Orionis Biosciences, Inc. |
Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
WO2019157124A1
(en)
|
2018-02-08 |
2019-08-15 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
|
SG11202008593PA
(en)
|
2018-03-21 |
2020-10-29 |
Five Prime Therapeutics Inc |
ANTIBODIES BINDING TO VISTA AT ACIDIC pH
|
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
EP3784688A2
(en)
|
2018-04-26 |
2021-03-03 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
CN112566938B
(zh)
|
2018-06-03 |
2025-04-01 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
|
MY201995A
(en)
|
2018-07-09 |
2024-03-28 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
|
CA3176812A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
AU2019301120A1
(en)
|
2018-07-11 |
2021-02-25 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
JP7072715B2
(ja)
|
2018-07-20 |
2022-05-20 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ１１２ｒ組成物及び方法
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
US20220267369A1
(en)
|
2018-07-25 |
2022-08-25 |
Merck Sharp & Dohme Corp. |
Methods of separating host cell lipases from a production protein in chromatographic processes
|
|
AU2019309849A1
(en)
|
2018-07-26 |
2021-03-18 |
Bristol-Myers Squibb Company |
LAG-3 combination therapy for the treatment of cancer
|
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
|
AU2019328632A1
(en)
|
2018-08-27 |
2021-03-25 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
|
|
US20210340279A1
(en)
|
2018-08-31 |
2021-11-04 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
|
WO2020044252A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Dosage regimes for anti-m-csf antibodies and uses thereof
|
|
CN118846110A
(zh)
|
2018-09-06 |
2024-10-29 |
第一三共株式会社 |
抗体药物偶联物
|
|
WO2020049534A1
(en)
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
CN112867803A
(zh)
|
2018-10-16 |
2021-05-28 |
诺华股份有限公司 |
单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
|
|
WO2020081928A1
(en)
|
2018-10-19 |
2020-04-23 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
EP3890773A4
(en)
|
2018-11-08 |
2022-11-09 |
Orionis Biosciences, Inc. |
MODULATION OF DENDRITIC CELL LINES
|
|
CA3119341A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル－マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
|
EA202191201A1
(ru)
|
2018-12-03 |
2022-01-26 |
Эдженсис, Инк. |
Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
|
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
|
CN109887035A
(zh)
*
|
2018-12-27 |
2019-06-14 |
哈尔滨理工大学 |
基于蝙蝠算法优化bp神经网络双目视觉标定
|
|
EP3911302B1
(en)
|
2019-01-17 |
2025-09-10 |
Georgia Tech Research Corporation |
Drug delivery systems containing oxidized cholesterols
|
|
EP3923940B1
(en)
|
2019-02-12 |
2025-12-03 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
|
|
HUE072069T2
(hu)
|
2019-02-12 |
2025-10-28 |
Sumitomo Pharma America Inc |
2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
|
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
|
|
AU2020245437A1
(en)
|
2019-03-22 |
2021-09-30 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
|
WO2020198665A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fibroblast activation protein binding agents and use thereof
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
CN114630675A
(zh)
|
2019-06-18 |
2022-06-14 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
|
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
AU2020350205A1
(en)
|
2019-09-18 |
2022-05-12 |
Lamkap Bio Alpha AG |
Bispecific antibodies against CEACAM5 and CD3
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021086909A1
(en)
|
2019-10-29 |
2021-05-06 |
Eisai R&D Managment Co., Ltd. |
Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
US20210154281A1
(en)
|
2019-11-26 |
2021-05-27 |
Massachusetts Institute Of Technology |
Cell-based cancer vaccines and cancer therapies
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
AU2021213969A1
(en)
|
2020-01-30 |
2022-09-01 |
ONA Therapeutics S.L. |
Combination therapy for treatment of cancer and cancer metastasis
|
|
IL295626A
(en)
|
2020-02-28 |
2022-10-01 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
|
|
WO2021176424A1
(en)
|
2020-03-06 |
2021-09-10 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
MX2022013031A
(es)
|
2020-04-21 |
2023-01-04 |
Novartis Ag |
Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r.
|
|
IL298019A
(en)
|
2020-05-13 |
2023-01-01 |
Massachusetts Inst Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
|
US12668777B2
(en)
|
2020-08-05 |
2026-06-30 |
Augusta University Research Institute, Inc. |
Chimeric antigen receptor T cells and methods of use thereof
|
|
US20230416364A1
(en)
|
2020-08-13 |
2023-12-28 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
KR20230121772A
(ko)
|
2020-12-18 |
2023-08-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
US20240423972A1
(en)
|
2021-02-01 |
2024-12-26 |
Yale University |
Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
WO2022256534A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
WO2023057534A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
EP4423249A1
(en)
|
2021-10-28 |
2024-09-04 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
EP4452327A1
(en)
|
2021-12-20 |
2024-10-30 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
EP4249498A1
(en)
*
|
2022-03-23 |
2023-09-27 |
Lipotrue, S.L. |
Peptides and compositions for use in cosmetics, food and medicine
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
CA3253038A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
|
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
|
CN119998319A
(zh)
|
2022-06-16 |
2025-05-13 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗
|
|
WO2024040264A1
(en)
|
2022-08-19 |
2024-02-22 |
Massachusetts Institute Of Technology |
Compositions and methods for targeting dendritic cell lectins
|
|
CN120379691A
(zh)
|
2022-09-30 |
2025-07-25 |
爱兰蒂斯疗法股份公司 |
耐药性肝细胞癌的治疗
|
|
JP2025536260A
(ja)
|
2022-10-11 |
2025-11-05 |
イェール ユニバーシティー |
細胞透過性抗体の組成物および使用方法
|
|
WO2024112867A1
(en)
|
2022-11-23 |
2024-05-30 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of use thereof for increasing immune responses
|
|
AU2023403103A1
(en)
|
2022-12-01 |
2025-07-10 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
CN120302979A
(zh)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
|
|
JP2026501506A
(ja)
|
2022-12-14 |
2026-01-16 |
アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ |
Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
EP4688160A1
(en)
|
2023-04-06 |
2026-02-11 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
|
EP4694894A1
(en)
|
2023-04-12 |
2026-02-18 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
IL324457A
(en)
|
2023-05-12 |
2026-01-01 |
Genmab As |
Antibodies capable of binding to ox40, their variants and uses thereof
|
|
CN121729432A
(zh)
|
2023-06-23 |
2026-03-24 |
派克西斯肿瘤学公司 |
抗klrg1抗体及其用途
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2025002264A1
(zh)
|
2023-06-30 |
2025-01-02 |
默沙东有限责任公司 |
包含偶联物的药物组合的治疗方法和用途
|
|
KR20260042361A
(ko)
|
2023-06-30 |
2026-03-31 |
머크 샤프 앤드 돔 엘엘씨 |
치료 조합물, 및 이의 용도 및 치료 방법
|
|
KR20260057078A
(ko)
|
2023-08-18 |
2026-04-27 |
브리스톨-마이어스 스큅 컴퍼니 |
Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
CN122249464A
(zh)
|
2023-11-30 |
2026-06-19 |
金麦安博股份有限公司 |
在组合疗法中的能够结合ox40的抗体
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2026006604A1
(en)
|
2024-06-26 |
2026-01-02 |
Lyell Immunopharma, Inc. |
Feeder cell replacement
|
|
WO2026057739A1
(en)
|
2024-09-12 |
2026-03-19 |
BioNTech SE |
Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
|
|
WO2026125485A1
(en)
|
2024-12-11 |
2026-06-18 |
BioNTech SE |
Anti-ctla4 antibodies for treating non-small cell lung cancer
|
|
WO2026136792A1
(en)
|
2024-12-20 |
2026-06-25 |
Nuvalent, Inc. |
Heteroaryl compounds as modulators of akt activity
|
|
CN119841936B
(zh)
*
|
2024-12-30 |
2025-09-30 |
中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) |
抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用
|